Clinical trial
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With…
NCT02672852 · AbbVie, Industry · Completed
Key facts
| NCT number | NCT02672852 |
|---|---|
| Title | BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment |
| Official title | BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance) |
| Lead sponsor | AbbVie, Industry |
| Collaborators | Boehringer Ingelheim Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Psoriasis |
| Intervention type | Drug |
| Interventions | Risankizumab, Placebo |
| Enrollment | 507 |
| Start date | Feb 29, 2016 |
| Primary completion | Aug 2, 2017 |
| Completion | Jul 26, 2018 |
| First posted | Feb 3, 2016 |
| Last update posted | Oct 9, 2019 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: